PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Innovation Would be the Best Method to Fight Generics Primacy in the Latin American Cardiovascular Drugs Markets - New analysis from Frost & Sullivan, Latin American Cardiovascular Drugs Markets, finds that market earned revenues of $1.49 billion in 2006 and estimates this to reach $3.33 billion in 2011
Innovation Would be the Best Method to Fight Generics Primacy in the Latin American Cardiovascular Drugs Markets

 

NewswireToday - /newswire/ - Buenos Aires, Argentina, 2008/04/17 - New analysis from Frost & Sullivan, Latin American Cardiovascular Drugs Markets, finds that market earned revenues of $1.49 billion in 2006 and estimates this to reach $3.33 billion in 2011.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

[April 16, 2008] – Latin American countries, due to their desire to mimic the lifestyles of developed countries, are increasingly falling prey to cardiovascular diseases (CVDs). This situation is providing valuable opportunities to pharmaceutical companies to develop drugs that can reduce drug interactions and offer better efficacy and safety profile.

New analysis from Frost & Sullivan (pharma.frost.com), Latin American Cardiovascular Drugs Markets, finds that market earned revenues of $1.49 billion in 2006 and estimates this to reach $3.33 billion in 2011.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the Latin American Cardiovascular Drugs Markets, then send an email to José María Jantus, Corporate Communications, at jose.jantus[.]frost.com, your full name, company name, title, telephone number, company e-mail address, company website, city, state, and country. Upon receipt of the above information, an overview will be sent to you by email.

The complexity of CVDs and their multiple causes and links with obesity and diabetes present interesting R&D prospects, especially in the area of metabolic disorders. There could be a marked shift away from the traditional goals of simply monitoring blood pressure and circulatory dynamics toward curing the underlying disease rather than the symptoms.

The new drugs should have fewer side effects, cover several disease conditions, and be affordable. Drug companies should also be prepared for the expiry of a number of patents in the near future, since this could cause global companies to lose their exclusivity and facilitate the market entry of generics.

If the market majors hope to retain their market shares, they should focus on innovating therapeutic classes so they can manage the current product lifecycle with brand extensions and activation of old product formulation. The current trend is to combine molecules, as drug developments are fewer in CVD than in other disease areas.

"Combinations are all the rage, given the relative increase in their effectiveness and the decrease in the number of daily tablets needed," say Luisa Woge, Research Analyst at Frost & Sullivan. "Although combinations seem to be the best way to efficiently manage the usual cardiovascular treatment goals in terms of blood pressure and cholesterol levels, diverse and uncommon therapeutic targets may be considered in the long term."

For instance, the evolution of genetic engineering could facilitate the use of gene therapy for curing cancer, AIDS, and cardiovascular conditions. It is hoped that the inhibition of specific genes or cells can help prevent the advancement of certain diseases.

Meanwhile, a rise in the number of the aged has caused a simultaneous increase in the prevalence of chronic conditions such as stroke and heart diseases. Since CVD is the most common cause of mortality among the aged, there will be a consequent hike in the purchase of cardiovascular drugs.

"Cardiovascular drugs are a high priority for many leading companies, because some patients tend to remain on medication for life," observes Woge. "In the short run, such boosting effect is not likely to be significant but it could be so in the next three to seven years."

The governments have expanded healthcare coverage for people from the lower socioeconomic levels, giving a boost to the cardiovascular drug market. However, due the paucity of adequate funds, they tend to opt for generic funds for their lower costs.

"Generic competition is becoming more aggressive, and in the future, generics' quality is expected to improve due to new bioequivalence regulations in the region," remarks Woge. "Also, governments are promoting generic prescription to drive the local pharmaceutical industry and guarantee better treatment, while these medicines are still inexpensive."

Generic drugs, having already penetrated a considerable part of the market, are likely to continue driving down prices and growing dynamically.

Latin American Cardiovascular Drugs Markets is part of the Pharmaceutical & Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: European cardiovascular drugs markets, Latin American diabetes therapy market, and Brazilian clinical diagnostics automation market. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting, and Career Best Practices empower clients to create a growth focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents.

Latin American Cardiovascular Drugs Markets N2AD

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Innovation Would be the Best Method to Fight Generics Primacy in the Latin American Cardiovascular Drugs Markets

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: José María Jantus 
+54-11-4777- 9951 jose.jantus[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)